Search

In 2009, Memorial Sloan Kettering established the nurse-led Cancer and Fertility Program to overcome barriers to getting information and provide resources to help clinicians have discussions about fertility options with their patients.

… Thursday, August 24, 2017 Access to information about fertility preservation and family-building options before and after cancer treatment is a key factor in the psychological wellbeing of young patients. But, unfortunately many of them don’t get adequate advice at the time that they need it. Each year

An MSK study reveals new details about how pancreatic cells carrying oncogenic mutations transition from benign to malignant — shining new light on the ecosystems that supports emerging tumors.

… Wednesday, April 15, 2026 As we age, our cells accumulate genetic changes — mutations — some of which open the door to cancer. Scientists call these mutations “oncogenic,” meaning “tumor producing.” By our senior years, we each may harbor as many as 100 billion cells with at least one oncogenic mutation

Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024.

… Friday, January 3, 2025 Arcascope, a leading digital health company specializing in sleep and circadian medicine, recently became the most recent company to join the MSK Innovation Hub in October 2024. Arcascope will pilot test Arcasync, an app for monitoring and managing sleep and circadian rhythms

MSK investigators presented new research on a range of important topics at the 2024 Annual Meeting of the American Association for Cancer Research.

… Tuesday, April 9, 2024 Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented new research on a range of important topics at the 2024 Annual Meeting of the American Association for Cancer Research (AACR). Among the dozens of studies reported were a clinical trial that evaluated a new

Memorial Sloan Kettering President Craig Thompson, his wife, scientist Tullia Lindsten, and husband-and-wife physician-scientists Yu Chen and Ping Chi, discuss the pleasures and challenges of dual-career marriages.

… Monday, December 23, 2013 On Thursday, November 20, 2013, Gerstner Sloan Kettering Women in Science sat down to lunch with Memorial Sloan Kettering President and CEO Craig B. Thompson  and his wife, scientist  Tullia Lindsten , along with married physician-scientists Yu Chen and Ping Chi . They were

Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.

… Friday, December 6, 2013 Summary Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines. A pioneering effort to speed the development of novel immunotherapies for cancer drew national headlines this week with the announcement

Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors.

… Friday, June 17, 2022 Sequencing circulating tumor cell-free DNA (cfDNA) in cerebrospinal fluid (CSF) improved diagnosis, decision-making, and clinical care in pediatric and adolescent and young adult (AYA) patients with brain tumors, according to clinical experience at Memorial Sloan Kettering Cancer

The evolution of the surgical management of regional lymph nodes in patients with melanoma is an extraordinary lesson in the importance of humility and open-mindedness for academic surgeons.

… Tuesday, January 12, 2016 Cancer research continues to question the standard of care to find new approaches to improve survival outcomes for patients. The evolution of the surgical management of regional lymph nodes in patients with melanoma is an extraordinary lesson in the importance of humility and

Learn about MSK's visionary plans for meeting the upcoming surge in cancer cases with state-of-the-art clinical care.

… Tuesday, September 3, 2024 The prognosis is sobering. “There is a coming surge of cancer cases, on top of the storm that is already upon us,” says Jeffrey Drebin, MD, PhD , Chair of Surgery at Memorial Sloan Kettering Cancer Center (MSK). According to the Centers for Disease Control and Prevention, the

Scientists have discovered an inherited gene variant that may reduce the risk of developing certain blood cancers.

… Thursday, January 1, 2026 Scientists have known for decades that there are gene mutations that increase your risk of developing cancer. But there is also a genetic variant that could reduce the risk of developing certain blood cancers, according to new research co-led by scientists from Memorial Sloan